LAUSR

Purpose BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients according to BRAF mutations, with the aim to identify any predictive factors of response to targeted-based therapy. Methods A retrospective study of RCC patients, with BRAF known mutation status, treated with chemotherapy (CT) from October 2008 to June 2019 in 5 Italian centers, was conducted. Results We identified 207 advanced RCC patients: 20.3% BRAF mutant and 79.7% BRAF wild type (wt). BRAF-mutant cancers were more likely to be pT4 (50.0% v 25.7%, p  = 0.016), undifferentiated (71.4% v 44.0%, p  = 0.004), KRAS wt (90.5% v 38.2%, p  < 0.001), and MSI-H (41.7% v 16.2%, p  = 0.019) tumors, with synchronous (52.4% v 31.5%, p  = 0.018) and peritoneal metastases (38.1% v 22.4%, p  = 0.003). Median overall survival (OS) was 16 v 27 months in BRAF mutant and BRAF wt ( P  = 0.020). In first-line setting, BRAF-mutant showed a 2ys OS of 80% in clinical trials, 32% in anti-VEGF, 14% in epidermial growth factor receptor (EGFR), and 0% in chemotherapy alone regimens ( P  = 0.009). BRAF-mutant patients demonstrated worse survival, regardless of targeted therapy administered. However, survival difference was statistically significant in the anti-EGFR-treated subgroup (16 v 28 months, P  = 0.005 in BRAF mutant v BRAF wt, respectively) . Conclusions Our study demonstrated that BRAF status makes the difference in treatment’s outcome. Therefore, the anti-EGFR should not be excluded in all advanced RCC but considered on a case-by-case basis.